Work

Cancer vaccines: shared tumor antigens return to the spotlight

Year: 2020

Type: article

Abstract: Sahin et al. recently reported interim data from a phase 1 clinical trial (NCT02410733) treating melanoma patients with a RNA-lipoplex vaccine (RNA-LPX), targeting melanoma TAA. 1 The trial is a multicenter, non-randomized, open-label, dose-escalation trial designed to evaluate the safety and tolerability of BNT111 targeting four melanoma TAA (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE). Secondary endpoints include vaccine-induced immune responses and clinical response of patients with measurable disease.

Source: Signal Transduction and Targeted Therapy

DOI: 10.1038/s41392-020-00364-8

Authors: Lijin Li, S. Peter Goedegebuure, William Gillanders

Institutions: Washington University in St. Louis, Barnes-Jewish Hospital, Alvin J. Siteman Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,680